Origami Therapeutics, Inc.

Origami Therapeutics is a biotechnology firm focused on creating innovative protein degradation therapies designed to slow or stop neurodegenerative diseases. Their approach involves eliminating harmful proteins from the body using novel oral drugs. The company's drug discovery platform utilizes proprietary human disease models, enabling the selection of small molecules with a higher likelihood of clinical success. Their initial focus is on Huntington’s disease, a severe and fatal genetic disorder. Origami Therapeutics has identified small molecules capable of reducing toxic mutated proteins, mitigating mutant protein-induced toxicities in human neurons, and effectively penetrating the brain. They believe this strategy can be extended to target previously "undruggable" proteins in various other neurological conditions, offering a promising avenue for treating these challenging diseases.